Research
Hormonal
Subcutaneous semaglutide (0.5-1.0 mg) and oral semaglutide (14 mg) effectively reduce body weight and HbA1c in patients with Type 2 Diabetes, with subcutaneous administration showing greater weight loss than oral administration in indirect comparisons.
For patients with Type 2 Diabetes, both subcutaneous (0.5-1.0 mg weekly) and oral (14 mg daily) semaglutide effectively reduce weight and blood sugar. Subcutaneous administration appears to produce greater weight loss than the oral form, though both are superior to other diabetes medications.
StrongSupportsHIGH confidence
Based on the analysis of 10 studies... it was found that semaglutide more effectively reduced the level of glycated hemoglobin (HbA1c), as well as the body mass of the subjects compared to placebo... However, in indirect comparison of results... we found that subcutaneous administration of semaglutide led to greater weight loss than oral.
Why this rating
Based on multiple Phase 3 RCTs (SUSTAIN 1-10, PIONEER 1-10).
Source
Semaglutide — effectiveness in weight loss and side effects when used according to studies by SUSTAIN, PIONEER, STEP
O. R. Shabutdinova et al. · Problems of Endocrinology · 2023
narrative_reviewCited 10×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →